ResMed (RMD) Stock Recommendation

ResMed (RMD) have an reiterated Outperform recommendation and a 12 month share price target of $7.08 from stock analyst Macquarie Research Equities (MRE). This health care sector stock is MRE's top pick of the sector followed by CSL and RHC. The stock analyst also expects ResMed to step up their spending on new product development to 6.5 percent of sales in the quarter which is up from 5.8 percent for FY06. MRE is expecting 29.9 percent growth to $165.2 million from ResMed. The stock analyst have noted that "ResMed's competitor Respironics (Nasdaq: RESP) has posted a decidedly weak first quarter. Further, Respironics recent product recall of around 172,000 flow generator units (around 15% of the installed base), gives further weight to the potential market share gains that RMD has at its finger-tips."

Resmed Limited is listed on the Australian Stock Exchange (ASX) under stock code RMD. You can view their investor website here. RMD was listed on the ASX on 25 November, 1999. Dr Peter Farrell is the current CEO for ResMed. The company was a Loser of the Week back in August 2006. ResMed is a leading developer, manufacturer and marketer of products for the screening, treatment and long-term management of sleep-disordered breathing (SDB) and other respiratory disorders. Find out the meaning of the recommendations in this primer. Browse for other stockbroker recommendations. Check your charts and good luck with your share trading!